Geron Corporation - Common Stock (NQ:GERN)

1.210 +0.010 (+0.83%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine

September 30, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:BIOA),(NASDAQ:GERN),(NASDAQ:DNLI) EQNX::TICKER_END

Via FinancialNewsMedia

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands ↗

September 16, 2026

Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company...

Via MarketBeat

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

September 14, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Geron (NASDAQ:GERN) Falls After Mixed Q2 Results; Revenue Beats but Loss Wider Than Expected ↗

August 05, 2026

Via Chartmill

Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continues ↗

May 06, 2026

Via Chartmill

Geron Corp (NASDAQ:GERN) Stock Plummets 10% After Q4 Revenue Miss ↗

February 25, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Geron Earnings Preview ↗

November 04, 2025

Via Benzinga

Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands ↗

September 13, 2026

Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company...

Via MarketBeat

Geron (GERN) Q2 2026 Earnings Call Transcript ↗

August 06, 2026

RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.

Via The Motley Fool

Topics Earnings

Geron Q2 Earnings Call Highlights ↗

August 05, 2026

Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with...

Via MarketBeat

Topics Earnings

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

May 20, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

Via FinancialNewsMedia

Geron (GERN) Q1 2026 Earnings Call Transcript ↗

May 07, 2026

Geron (GERN) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Economy

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

March 03, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

Via FinancialNewsMedia

Here are the top movers in Wednesday's session. ↗

February 25, 2026

Via Chartmill

Geron (GERN) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Geron (GERN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Which stocks are moving before the opening bell on Wednesday? ↗

February 25, 2026

Via Chartmill

Why Did GERN Stock Tumble 10% Pre-Market Today? ↗

February 25, 2026

Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates.

Via Stocktwits

Topics Artificial Intelligence

Geron Corp (NASDAQ:GERN) Reports Mixed Q3 2025 Results, Misses Revenue Estimates ↗

November 05, 2025

Geron's Q3 2025 results show mixed performance, with RYTELO revenue up 67% year-over-year but missing analyst sales estimates, causing a negative market reaction.

Via Chartmill

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 05, 2025

From Geron Corporation

Via Business Wire

Geron Corporation to Present at Upcoming Investor Conferences

November 04, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

November 03, 2025

From Geron Corporation

Via Business Wire

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 27, 2025

From Geron Corporation

Via Business Wire

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 23, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 20, 2025

From Geron Corporation

Via Business Wire

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

August 27, 2025

From Geron Corporation

Via Business Wire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025

From Geron Corporation

Via Business Wire

GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

August 13, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 08, 2025

From Geron Corporation

Via Business Wire

Geron (GERN) Q2 Revenue Jumps 5,477% ↗

August 06, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.